Results 91 to 100 of about 14,439 (224)
Biosimilars in rheumatology: what the clinician should know
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars ...
Jonathan Kay +3 more
doaj +1 more source
Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine ...
Pokphazz Christjaroon +4 more
wiley +1 more source
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma +5 more
wiley +2 more sources
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Biosimilars in Gynecologic Cancers: Basic Principles and New Horizons
Biological therapies have transformed cancer treatment by targeting the molecular mechanisms involved in carcinogenesis. However, higher costs, limited accessibility, and supply chain disruptions—such as those caused by COVID-19 in recent years ...
Mariem Galuia +2 more
doaj +1 more source
Health technology assessment of biosimilars worldwide: a scoping review
Background Health technology assessment (HTA) should provide an assessment of a technology’s effects on health and of the related social, economic, organisational and ethical issues. HTA reports on biosimilars can specifically assess their immunogenicity,
Bruna de Oliveira Ascef +2 more
doaj +1 more source
Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis +4 more
wiley +1 more source
Biosimilars in oncology: key role of nurses in patient education
Biosimilars have the potential to lower costs and increase patient access to life-saving cancer therapies. However, lack of familiarity with biosimilars can be a barrier to their adoption, limiting their health and economic benefits.
Waller, Cornelius F. +1 more
core +1 more source
Biologic drugs are large, complex molecules produced through biotechnology. A biosimilar is a biologic product that is highly similar to an already approved biologic (reference product), with no clinically meaningful differences in purity, safety, or efficacy; as such, a biosimilar does not need to undergo the same level of study in a clinical trial ...
Sheridan, Maria +2 more
openaire +3 more sources
Denosumab discontinuation and fracture risk: getting the balance right
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley +1 more source

